| Literature DB >> 31281289 |
Jo Max Goodson1, Markus Hardt1, Mor-Li Hartman1, Hend Alqaderi1,2, Daniel Green1, Mary Tavares1, Al-Sabiha Mutawa3, Jitendra Ariga2, Pramod Soparkar1, Jawad Behbehani4, Kazem Behbehani5.
Abstract
In a longitudinal study of 6,158 Kuwaiti children, we selected 94 for salivary metabolomic analysis who were neither obese (by waist circumference) nor metabolic syndrome (MetS) positive (<3 diagnostic features). Half (43) remained healthy for 2 years. The other half (51) were selected because they became obese and MetS positive 2 years later. In the half becoming obese, metabolomic analysis revealed that the level of salivary N1-Methyl-2-pyridone-5-carboxamide (2PY) had the highest positive association with obesity (p = 0.0003, AUC = 0.72) of 441 salivary biochemicals detected. 2PY is a recognized uremic toxin. Also, 2PY has been identified as a biomarker for uranium uptake. Considering that a relatively recent military conflict with documented uranium contamination of the area suggests that this weight gain could be a toxicological effect of long-time, low-level uranium ingestion. Comparison of salivary 2PY in samples from the USA and Kuwait found that only Kuwait samples were significantly related to obesity. Also, the geographic distribution of both reported soil radioactivity from 238U and measured salivary 2PY was highest in the area where military activity was highest. The prevalence pattern of adult diabetes in Kuwait suggests that a transient diabetogenic factor has been introduced into the Kuwaiti population. Although we did not measure uranium in our study, the presence of a salivary biomarker for uranium consumption suggests potential toxicity related to obesity in children.Entities:
Keywords: 2PY; N1-Methyl-2-pyridone-5-carboxamide; adolescent obesity; kuwaiti children; metabolic syndrome; nicotinate metabolism; uranium toxicity
Year: 2019 PMID: 31281289 PMCID: PMC6596350 DOI: 10.3389/fendo.2019.00382
Source DB: PubMed Journal: Front Endocrinol (Lausanne) ISSN: 1664-2392 Impact factor: 5.555
Figure 1The design of this study which selected 94 children from a longitudinal study of two visits. The metabolic disease category was selected such that 51 were not obese at the first visit and became obese 2 years later at the second visit (the disease group). The 43 control subjects (the healthy group), were selected for not having obesity at either visit. Mets count is the sum of 4 binary metabolomic syndrome characteristics (obesity by waist circumference + high blood pressure + high salivary glucose + low salivary cholesterol).
Anthropometric values of children at V1 and V2.
| Age V1(y) | 9.8 ± 0.6 | 9.8 ± 0.6 | −0.03 | 0.8 | 2.08 ± 0.13 | 2.1 ± 0.12 | 0.4 |
| Age V2(y) | 11.9 ± 0.6 | 11.9 ± 0.6 | −0.05 | 0.7 | |||
| Waist circumference V1 (cm) | 68.4 ± 5.4 | 60.1 ± 5.8 | 8.30 | <0.0001 | 20.65 ± 6.19 | 8.26 ± 7.87 | <0.0001 |
| Waist circumference V2 (cm) | 89.1 ± 4.6 | 68.4 ± 9.2 | 20.68 | <0.0001 | |||
| BMI V1(Kg/m2) | 21.0 ± 2.2 | 17.1 ± 1.8 | 3.93 | <0.0001 | 5.02 ± 1.78 | 1.43 ± 1.69 | <0.0001 |
| BMI V2 (Kg/m2) | 26.0 ± 1.5 | 18.5 ± 2.4 | 7.51 | <0.0001 | |||
| Systolic BP V1(mmHg) | 112.9 ± 14.9 | 103.7 ± 15.4 | 9.23 | 0.004 | 16.69 ± 18.01 | 5.35 ± 22.72 | 0.008 |
| Systolic BP V2(mmHg) | 129.6 ± 11.7 | 109.0 ± 16.0 | 20.57 | <0.0001 | |||
| Diastolic BP V1(mmHg) | 77.4 ± 13.0 | 67.7 ± 10.3 | 12.39 | 0.0001 | 12.39 ±17.17 | 8.58 ±16.5 | 0.3 |
| Diastolic BP V2(mmHg) | 89.8 ± 11.7 | 76.3 ± 13.5 | 8.58 | <0.0001 | |||
| Height V1 (cm) | 138.3 ± 6.7 | 134.3 ± 7.5 | 4.08 | 0.006 | 13.12 ± 3.70 | 13.16 ± 3.70 | 0.95 |
| Height V2 (cm) | 151.5 ± 6.7 | 147.4 ± 9.0 | 4.03 | 0.02 | |||
| Weight V1(Kg) | 40.3 ± 5.6 | 31.1 ± 6.2 | 9.19 | <0.0001 | 19.57 ± 4.29 | 9.5 ± 4.58 | <0.0001 |
| Weight V2(Kg) | 59.9 ± 6.4 | 40.6 ± 8.5 | 19.26 | <0.0001 | |||
| Male | 22 | 22 | |||||
| Female | 29 | 21 | |||||
P-values were computed by t-test and indicate the probability that differences between healthy and metabolic disease children were due to chance alone. Mean values ± standard deviations are listed for metabolic disease and healthy subjects. BMI, Body mass index; BP, Blood pressure.
Analysis of salivary metabolite associations with obesity (second visit) for p ≤ 0.01 in predicting obesity (Mann-Whitney U-test).
| N1-Methyl-2-pyridone-5-carboxamide | Cofactors and Vitamins | Nicotinate and Nicotinamide Metabolism | 0.0003 | 0.72 |
| Urate | Nucleotide | Purine Metabolism, (Hypo)Xanthine/Inosine containing | 0.0005 | 0.71 |
| Sphingomyelin (d18:1/24:1, d18:2/24:0) | Lipid | Sphingolipid metabolism | 0.002 | 0.64 |
| Gamma-glutamylphenylalanine | Peptide | Gamma-glutamyl amino acid | 0.002 | 0.56 |
| Acisoga | Amino acid | Polyamine metabolism | 0.005 | 0.67 |
| Phosphate | Energy | Oxidative phosphorylation | 0.01 | 0.65 |
| Threonylphenylalanine | Peptide | Dipeptide | 0.01 | 0.65 |
| Acetylcarnitine | Lipid | Fatty acid metabolism(Acyl Carnitine) | 0.01 | 0.65 |
| Arginine | Amino acid | Urea cycle; Arginine and Proline metabolism | 0.01 | 0.65 |
| 1-stearoyl-GPC (18:0) | Lipid | Lysolipid | 0.0002 | 0.73 |
| docosahexaenoate (DHA; 22:6n3) | Lipid | Polyunsaturated Fatty Acid (n3 and n6) | 0.001 | 0.69 |
| N-acetylglycine | Amino Acid | Glycine, Serine and Threonine Metabolism | 0.001 | 0.69 |
| 1-stearoyl-2-linoleoyl-GPC (18:0/18:2) | Lipid | Phospholipid Metabolism | 0.002 | 0.69 |
| 1-stearoyl-GPE (18:0) | Lipid | Lysolipid | 0.002 | 0.68 |
| 1-palmitoyl-2-arachidonoyl-GPC (16:0/20:4) | Lipid | Phospholipid Metabolism | 0.003 | 0.68 |
| oleoylcarnitine | Lipid | Fatty Acid Metabolism(Acyl Carnitine) | 0.003 | 0.64 |
| 2'-deoxyinosine | Nucleotide | Purine Metabolism, (Hypo)Xanthine/Inosine containing | 0.004 | 0.65 |
| cholesterol | Lipid | Sterol | 0.005 | 0.67 |
| 1-palmitoyl-2-oleoyl-GPC (16:0/18:1) | Lipid | Phospholipid Metabolism | 0.008 | 0.66 |
| isobutyrylcarnitine | Amino Acid | Leucine, Isoleucine and Valine Metabolism | 0.009 | 0.56 |
| 1-palmitoyl-2-linoleoyl-GPC (16:0/18:2) | Lipid | Phospholipid Metabolism | 0.009 | 0.66 |
| 1-palmitoyl-GPC (16:0) | Lipid | Lysolipid | 0.010 | 0.74 |
| arachidonate (20:4n6) | Lipid | Polyunsaturated Fatty Acid (n3 and n6) | 0.01 | 0.65 |
| sphingomyelin (d18:1/14:0, d16:1/16:0) | Lipid | Sphingolipid Metabolism | 0.01 | 0.60 |
| 1-(1-enyl-stearoyl)-2-linoleoyl-GPE (P-18:0/18:2) | Lipid | Plasmalogen | 0.01 | 0.58 |
The top ten biochemicals (upper panel) all increased in obese children. Sixteen biochemicals that significantly decreased in the saliva of obese children are listed in the lower panel.
Analysis of salivary metabolite associations with obesity (first visit) for p ≤ 0.01 in predicting obesity (Mann-Whitney U-test).
| Nicotinate ribonucleoside | Cofactors and Vitamins | Nicotinate and Nicotinamide Metabolism | 0.00007 | 0.73 |
| Xanthosine | Nucleotide | Purine Metabolism, (Hypo)Xanthine/Inosine containing | 0.004 | 0.67 |
| Phenol sulfate | Amino Acid | Phenylalanine and Tyrosine Metabolism | 0.004 | 0.67 |
| Phosphoenolpyruvate (PEP) | Carbohydrate | Glycolysis, Gluconeogenesis, and Pyruvate Metabolism | 0.006 | 0.66 |
| Sulfate | Xenobiotics | Chemical | 0.001 | 0.70 |
| Caffeine | Xenobiotics | Xanthine metabolism | 0.005 | 0.55 |
| Ribitol | Carbohydrate | Pentose metabolism | 0.01 | 0.55 |
| Phenylacetate | Amino Acid | Phenylalanine and tyrosine metabolism | 0.01 | 0.65 |
| 4-hydroxyphenylacetate | Amino Acid | Phenylalanine and tyrosine metabolism | 0.01 | 0.65 |
The top four biochemicals (upper panel) all increased in obese children. Five biochemicals that significantly decreased in the saliva of obese children are listed in the lower panel.
Analysis of covariance in the prediction of BMI and systolic blood pressure by salivary biomarkers (N = 94, correlation coefficients = 0.48 for BMI and 0.42 for systolic bp).
| Age | 0.60 | 0.24 |
| Sex | 0.27 | 0.57 |
| N1-methyl-2-pyridone-5-carboxamide (2PY) | 0.01 | 0.12 |
| Urate | 0.45 | 0.04 |
| Acisoga | 0.65 | 0.81 |
| Phosphate | 0.53 | 0.81 |
| Isobutyrylcarnitine | 0.19 | 0.03 |
The difference in the normalized spectral abundance of N1-Methyl-2-pyridone-5- carboxamide in saliva samples from obese and not obese children from the USA compared to Kuwait.
| 1 | USA | 10.7 | 22 | 1.187 | 46 | 1.037 | 68 | 0.46 | 2/23/2011 |
| 2 | USA | 12.2 | 15 | 1.181 | 26 | 0.960 | 41 | 0.16 | 8/16/2012 |
| 3 | Kuwait | 10.1 | 50 | 1.008 | 100 | 0.675 | 150 | 0.0006 | 3/26/2013 |
| 4 | Kuwait V2 | 11.9 | 51 | 1.367 | 43 | 0.948 | 94 | 0.0003 | 11/3/2015 |
Saliva samples from Kuwait exhibited a highly significant difference between obese and those not obese whereas this difference in samples from the USA was not significant by t-test. Study 4 is the study analyzed in this manuscript and described in .
Figure 2(A) Average salivary N1-Methyl-2-pyridone-5-carboxamide (2PY) in Kuwaiti children by mass spectrometry and 238U activity concentration (4) in soil following remediation completed after the Gulf War. The principal military facility was located at Camp Doha in the Al Asimah governorate (capital) where both 2PY and 238U soil radioactivity were greatest. (B) Average BMI of children in each Kuwaiti governorate for V1 (n = 8,317) and V2 (n = 6,317). (C) Relative position of each governorate to Camp Doha. Graphic whiskers in (A,B) represent the standard error of the mean for each governorate.
Figure 3Prevalence of adult (20–79 years old) diabetes in Kuwait and the United States of America from 2000 to 2017. (Data from the International Diabetes Federation, https://www.idf.org/).